Pseudobulbar Affect (PBA), also known as emotional lability, pathological crying and laughing, or pseudobulbar cry, is a neurological disorder characterized by involuntary, inappropriate, and often uncontrollable episodes of crying or laughing that are disproportionate to or unrelated to the patient's emotional state [@schiffer2005]. These emotional outbursts can be triggered by minor stimuli or may occur spontaneously, causing significant distress and social embarrassment for affected individuals.
PBA results from damage to the neural pathways that regulate emotional expression. Unlike normal emotional responses, PBA episodes are not connected to the patient's true feelings and often occur in inappropriate contexts. For example, a patient may burst into laughter when hearing sad news or cry uncontrollably during a happy occasion [@cummings2006].
The condition is estimated to affect approximately 1-2 million people in the United States, though it is likely underdiagnosed due to lack of awareness among healthcare providers and patients alike [@brooks2008]. PBA can significantly impact quality of life, interfering with social interactions, relationships, and daily activities.
PBA results from disruption of the corticobulbar tract, which connects the cerebral cortex to the brainstem nuclei responsible for emotional expression. This pathway helps regulate the appropriate expression of emotions based on contextual social cues [@parvizi2001]. When this circuitry is damaged, there is a loss of cortical inhibition over brainstem emotional response centers, leading to uncontrolled emotional outbursts.
The condition involves dysfunction in several brain regions:
Research suggests that PBA involves dysregulation of neurotransmitter systems, particularly [@lauterbach2013]:
The degeneration or injury to specific neuron populations leads to imbalance between excitatory and inhibitory signals, resulting in inappropriate emotional expression. [@lauterbach2013]
PBA is most commonly associated with the following neurological conditions:
Amyotrophic Lateral Sclerosis (ALS): Up to 50% of ALS patients experience PBA symptoms, making it one of the most common associated conditions [@thakore2017]. The degeneration of upper motor neurons in the corticobulbar tract disrupts emotional regulation pathways.
Frontotemporal Dementia (FTD): PBA occurs in approximately 10-15% of FTD patients, often presenting early in the disease course [@mendez2006]. The degeneration of frontal and temporal brain regions disrupts emotional control mechanisms.
Alzheimer's Disease: While less common than in ALS or FTD, PBA can occur in 5-10% of Alzheimer's patients, particularly in moderate to advanced stages [@starkstein1995].
Parkinson's Disease: Some Parkinson's patients experience PBA, though it is less well-characterized than in other movement disorders.
Multiple System Atrophy (MSA): PBA has been reported in MSA patients, often accompanying other autonomic and motor symptoms.
Traumatic brain injury (TBI), especially when involving diffuse axonal injury or damage to frontal lobes, can result in PBA. Estimates suggest 5-10% of TBI survivors develop PBA [@zeilig2019].
Diagnosis of PBA is primarily clinical, based on:
The Pathological Laughter and Crying Scale (PLACS) is a validated tool used to assess PBA severity [@robinson1993]. Healthcare providers also use the:
It is essential to differentiate PBA from:
The only FDA-approved medication specifically for PBA is dextromethorphan/quinidine [@pioro2014]:
Off-label treatments include [@drayton2002]:
These agents modulate serotonin and norepinephrine pathways, helping stabilize emotional regulation.
PBA significantly affects multiple domains: